Whole Body Physiologically Based Pharmacokinetic Model to Explain A Patient With Drug-Drug Interaction Between Voriconazole and Flucloxacillin.

Heshu Abdullah-KoolmeesJulia F van den NieuwendijkSimone M K Ten HoopeDavid C de LeeuwLinda G W FrankenMedhat M SaidMaarten R SeefatEleonora L SwartN Harry HendrikseImke H Bartelink

Published in: European journal of drug metabolism and pharmacokinetics (2024)

Ex vivo experiments reported that the unbound voriconazole plasma concentration remained unchanged after adding flucloxacillin. The PBPK model describes the potential mechanism driving the drug-drug and drug-disease interaction of voriconazole and flucloxacillin, highlighting the large substantial influence of flucloxacillin on the PXR gene and the influence of infection on voriconazole plasma concentrations, and suggests a more limited effect on other triazoles.

Keyphrases

adverse drug
drug induced
emergency department
dna methylation
genome wide
case report
risk assessment
human health